{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:10:21Z","timestamp":1794575421441,"version":"4.9.1"},"reference-count":87,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Denosumab is a highly effective treatment for osteoporosis, and its long-term use is associated with incremental gains in BMD and sustained fracture risk reduction. Stopping denosumab, however, results in a rebound increase in bone turnover, loss of treatment-associated BMD gains, and in the worst case, spontaneous vertebral fractures (VFs). Insights into the risk factors, the underlying mechanisms for rebound-associated bone loss, and true incidence of rebound VFs are emerging. Conventional strategies using bisphosphonates to mitigate post-denosumab rebound display mixed success. Bisphosphonates may preserve bone density following short-term denosumab but the optimal sequential approach after longer-term denosumab remains elusive. Patients at particular risk of are those with prevalent VFs or greater on-treatment BMD gains. To greater understand these risks and strategies to preserve bone after denosumab, an emerging body of translational and preclinical work is shedding new light on the biology of RANKL inhibition and withdrawal. Discovering an effective \u201cexit strategy\u201d to control rebound bone turnover and avoid bone loss after denosumab will improve confidence among patients and clinicians in this highly effective and otherwise safe treatment for osteoporosis. This perspective characterizes the clinical problem of post-denosumab rebound, provides a comprehensive update on human studies examining the use of bisphosphonates following denosumab and explores mechanistic insights from preclinical studies that will be critical in the design of definitive human trials.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf037","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:24:25Z","timestamp":1741130665000},"page":"1017-1034","source":"Crossref","is-referenced-by-count":73,"title":["Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-2476","authenticated-orcid":false,"given":"Shejil","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Royal North Shore Hospital , Sydney, NSW 2065 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-5117","authenticated-orcid":false,"given":"Mawson","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Concord Repatriation General Hospital , Sydney, NSW 2137 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-0224","authenticated-orcid":false,"given":"Albert S","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]},{"name":"Cancer Ecosystems Theme, Garvan Institute of Medical Research , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5278-4527","authenticated-orcid":false,"given":"Jacqueline R","family":"Center","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]},{"name":"Garvan Institute of Medical Research , Sydney, NSW 2010 ,","place":["Australia"]},{"name":"St Vincent\u2019s Hospital Clinical School, UNSW , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-2506","authenticated-orcid":false,"given":"Michelle M","family":"McDonald","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW 2052 ,","place":["Australia"]},{"name":"Cancer Ecosystems Theme, Garvan Institute of Medical Research , Sydney, NSW 2010 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-5529","authenticated-orcid":false,"given":"Christian M","family":"Girgis","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Westmead Hospital , Sydney, NSW 2145 ,","place":["Australia"]},{"name":"Department of Diabetes and Endocrinology, Royal North Shore Hospital , Sydney, NSW 2065 ,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, NSW 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"issue":"6","key":"2025090306421125500_ref1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength","volume":"5","author":"Kostenuik","year":"2005","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"2025090306421125500_ref2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2025090306421125500_ref3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2025090306421125500_ref4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00198-021-06291-w","article-title":"Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study","volume":"33","author":"Lai","year":"2022","journal-title":"Osteoporos Int"},{"issue":"7","key":"2025090306421125500_ref5","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"30","key":"2025090306421125500_ref6","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025090306421125500_ref7","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025090306421125500_ref8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"2025090306421125500_ref9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090306421125500_ref10","doi-asserted-by":"publisher","first-page":"115287","DOI":"10.1016\/j.bone.2020.115287","article-title":"Favorable skeletal benefit\/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed","volume":"134","author":"Ferrari","year":"2020","journal-title":"Bone"},{"issue":"1","key":"2025090306421125500_ref11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"issue":"6","key":"2025090306421125500_ref12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","article-title":"Osteoclast recycling and the rebound phenomenon following denosumab discontinuation","volume":"20","author":"Kim","year":"2022","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"2025090306421125500_ref13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"11","key":"2025090306421125500_ref14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025090306421125500_ref15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025090306421125500_ref16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"key":"2025090306421125500_ref17","doi-asserted-by":"publisher","first-page":"116925","DOI":"10.1016\/j.bone.2023.116925","article-title":"Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: a retrospective study of patients with osteoporosis in a real-world clinical setting","volume":"177","author":"Cruchelow","year":"2023","journal-title":"Bone"},{"issue":"6","key":"2025090306421125500_ref18","doi-asserted-by":"publisher","first-page":"e10629","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate drug holidays: evidence from clinical trials and real-world studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"},{"issue":"4","key":"2025090306421125500_ref19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025090306421125500_ref20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025090306421125500_ref21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025090306421125500_ref22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025090306421125500_ref23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2025090306421125500_ref24","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025090306421125500_ref25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed denosumab injections and fracture risk among patients with osteoporosis : a population-based cohort study","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025090306421125500_ref26","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone"},{"issue":"6","key":"2025090306421125500_ref27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025090306421125500_ref28","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025090306421125500_ref29","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090306421125500_ref30","doi-asserted-by":"publisher","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","article-title":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study","volume":"144","author":"Everts-Graber","year":"2021","journal-title":"Bone"},{"key":"2025090306421125500_ref31","doi-asserted-by":"publisher","first-page":"116764","DOI":"10.1016\/j.bone.2023.116764","article-title":"Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study","volume":"172","author":"Liebich","year":"2023","journal-title":"Bone"},{"issue":"11","key":"2025090306421125500_ref32","doi-asserted-by":"publisher","first-page":"e2443899","DOI":"10.1001\/jamanetworkopen.2024.43899","article-title":"Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2025090306421125500_ref33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-21-0157","article-title":"Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence","volume":"185","author":"Grassi","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025090306421125500_ref34","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025090306421125500_ref35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.11005\/jbm.2021.28.1.51","article-title":"Zoledronic acid after treatment with denosumab is associated with bone loss within 1 year","volume":"28","author":"Kadaru","year":"2021","journal-title":"J Bone Metab"},{"issue":"6","key":"2025090306421125500_ref36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2025090306421125500_ref37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025090306421125500_ref38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","article-title":"Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis","volume":"31","author":"Ebina","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"3","key":"2025090306421125500_ref39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jocd.2022.03.001","article-title":"Bone mass gains after one denosumab injection followed by zoledronate","volume":"25","author":"Everts-Graber","year":"2022","journal-title":"J Clin Densitom"},{"issue":"5","key":"2025090306421125500_ref40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","article-title":"Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension","volume":"36","author":"Ramchand","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025090306421125500_ref41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-023-01119-7","article-title":"The five-year effect of a single zoledronate infusion on bone mineral density following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"113","author":"Anastasilakis","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2025090306421125500_ref42","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025090306421125500_ref43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","article-title":"The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial","volume":"35","author":"Ramchand","year":"2024","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025090306421125500_ref44","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","article-title":"One versus 2 years of alendronate following denosumab: the CARD extension","volume":"35","author":"Tsai","year":"2024","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025090306421125500_ref45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"2025090306421125500_ref46","doi-asserted-by":"publisher","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep"},{"issue":"7","key":"2025090306421125500_ref47","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025090306421125500_ref48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00223-022-00962-4","article-title":"Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis","volume":"111","author":"Hong","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2025090306421125500_ref49","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","article-title":"The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation","volume":"106","author":"Makras","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025090306421125500_ref50","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2025090306421125500_ref51","doi-asserted-by":"publisher","first-page":"116498","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"},{"issue":"7","key":"2025090306421125500_ref52","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025090306421125500_ref53","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"2025090306421125500_ref54","doi-asserted-by":"publisher","first-page":"100289","DOI":"10.1016\/j.bonr.2020.100289","article-title":"Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice","volume":"13","author":"Omiya","year":"2020","journal-title":"Bone Rep"},{"issue":"4","key":"2025090306421125500_ref55","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","article-title":"Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition","volume":"39","author":"Kim","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025090306421125500_ref56","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"2025090306421125500_ref57","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4720958\/v1","article-title":"Mouse model of uncoupled bone remodeling upon discontinuation of anti-RANKL antibody therapy (pre-print)","author":"Negishi-Koga","year":"2024","journal-title":"Bone Research"},{"key":"2025090306421125500_ref58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bone.2016.08.010","article-title":"The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: the TRIO study","volume":"92","author":"Gossiel","year":"2016","journal-title":"Bone"},{"issue":"4","key":"2025090306421125500_ref59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00784-015-1550-0","article-title":"Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow","volume":"20","author":"Kuroshima","year":"2016","journal-title":"Clin Oral Investig"},{"issue":"2","key":"2025090306421125500_ref60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.11005\/jbm.2022.29.2.93","article-title":"Effect of denosumab on the change of osteoclast precursors compared to zoledronate treatment in postmenopausal women with osteoporosis","volume":"29","author":"Kong","year":"2022","journal-title":"J Bone Metab"},{"issue":"2","key":"2025090306421125500_ref61","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-023-06931-3","article-title":"The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection","volume":"35","author":"Makras","year":"2024","journal-title":"Osteoporos Int"},{"issue":"18","key":"2025090306421125500_ref62","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI","volume":"8","author":"Fu","year":"2023","journal-title":"Insight"},{"issue":"3","key":"2025090306421125500_ref63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","article-title":"Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption","volume":"34","author":"Solling","year":"2023","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025090306421125500_ref64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025090306421125500_ref65","doi-asserted-by":"publisher","first-page":"1364694","DOI":"10.3389\/fphys.2024.1364694","article-title":"Osteocyte-mediated mechanical response controls osteoblast differentiation and function","volume":"15","author":"Buck","year":"2024","journal-title":"Front Physiol"},{"issue":"1","key":"2025090306421125500_ref66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41413-024-00362-4","article-title":"Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect","volume":"12","author":"El-Masri","year":"2024","journal-title":"Bone Res"},{"issue":"11","key":"2025090306421125500_ref67","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025090306421125500_ref68","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf008","article-title":"Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of RANKL inhibition","volume":"40","author":"Kim","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025090306421125500_ref69","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00223-023-01065-4","article-title":"Mitigating the Denosumab-induced rebound phenomenon with alternating short- and long-acting anti-resorptive therapy in a young boy with severe OI type VI","volume":"112","author":"Seale","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2025090306421125500_ref70","doi-asserted-by":"publisher","first-page":"e10731","DOI":"10.1002\/jbm4.10731","article-title":"Discontinuation of denosumab: gradual decrease in doses preserves half of the Bone mineral density gain at the lumbar spine","volume":"7","author":"Laroche","year":"2023","journal-title":"JBMR Plus"},{"key":"2025090306421125500_ref71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bcp.2019.06.027","article-title":"Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons","volume":"168","author":"Vargas-Franco","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2025090306421125500_ref72","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025090306421125500_ref73","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"key":"2025090306421125500_ref74","doi-asserted-by":"publisher","first-page":"635056","DOI":"10.3389\/fbioe.2021.635056","article-title":"Combined effects of exercise and Denosumab treatment on local failure in post-menopausal osteoporosis-insights from Bone remodelling simulations accounting for mineralisation and damage","volume":"9","author":"Martinez-Reina","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"2025090306421125500_ref75","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fendo.2020.00250","article-title":"Elevated Bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation","volume":"11","author":"Jahn-Rickert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2025090306421125500_ref76","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/jbmr.3954","article-title":"Apoptotic osteocytes induce RANKL production in bystanders via purinergic signaling and activation of Pannexin channels","volume":"35","author":"McCutcheon","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"9999","key":"2025090306421125500_ref77","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"28","key":"2025090306421125500_ref78","doi-asserted-by":"publisher","first-page":"20122","DOI":"10.1074\/jbc.M112.441360","article-title":"Parathyroid hormone (PTH)\/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH","volume":"288","author":"Saini","year":"2013","journal-title":"J Biol Chem"},{"issue":"7","key":"2025090306421125500_ref79","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus."},{"issue":"6","key":"2025090306421125500_ref80","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","article-title":"Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment","volume":"33","author":"Tominaga","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025090306421125500_ref81","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"2","key":"2025090306421125500_ref82","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","article-title":"Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women","volume":"40","author":"Hong","year":"2025","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025090306421125500_ref83","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","article-title":"A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis","volume":"35","author":"Kumar","year":"2024","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025090306421125500_ref84","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","article-title":"Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study","volume":"8","author":"Adami","year":"2024","journal-title":"JBMR Plus"},{"key":"2025090306421125500_ref85","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2019.04.022","article-title":"Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization","volume":"125","author":"Martinez-Reina","year":"2019","journal-title":"Bone"},{"issue":"1","key":"2025090306421125500_ref86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jbmr\/zjad018","article-title":"Bone loss after discontinuation of denosumab: the devil is in the details","volume":"39","author":"Minisola","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2025090306421125500_ref87","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SAT-532","article-title":"Bisphosphonates prevent bone loss associated with denosumab treatment discontinuation","volume":"3","author":"Zanchetta","year":"2019","journal-title":"J Endocr Soc"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf037\/62352239\/zjaf037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/9\/1017\/62352239\/zjaf037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/40\/9\/1017\/62352239\/zjaf037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:42:21Z","timestamp":1756896141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/40\/9\/1017\/8064740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":87,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,3,9]]},"published-print":{"date-parts":[[2025,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf037","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,9]]}}}